New targeted drug T320 enters first human tests for advanced cancers
Disease control
Not yet recruiting
This early-phase study tests a new drug, T320, in about 150 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if T320 can shrink tumors. Participants receive T320 every two weeks, and …
Phase: PHASE1 • Sponsor: Nanolattix Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 04, 2026 16:23 UTC